Mineralys Therapeutics, Inc. (MLYS)
Nasdaq · Healthcare · Biotechnology
$23.30−1.40%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.1B
- 52-week range
- $22.30 – $47.65
- 52-week change
- −37.83%
- EPS (trailing)
- −$4.22
- Next earnings
- Nov 10, 2026
Fiscal year to Dec 2025
- Net income
- −$155M
- Diluted EPS
- −$2.29
- Free cash flow
- −$142M
From the company’s annual report on SEC EDGAR.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Headquarters: Radnor, United States · 76 employees · mineralystx.com